“MediWound Ltd. (MDWD)… To this end, DeGeeter rates MDWD an Outperform along with a $7 price target. Should his thesis play out, a potential twelve-month gain of 117% could be in the cards… UroGen Pharma (URGN)… To this end, Gershell… Continue Reading…